VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Some cancer cells mimic stem cells to evade chemotherapy

Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

25 Sep 2007

Some cancer cells mimic stem cells to evade chemotherapy

Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented in Atlanta, Georgia at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

20 Sep 2007

Fat: An active player in the regulation of many processes in health and disease

Why should we be interested in doing obesity-related research? Emphasis is put on this type of research simply because of the fact that the epidemiological data and predictions are alarming. Worldwide it is estimated that one person in every eight is overweight and more than 300 millions are obese

3 Sep 2007

Blocking angiogenesis signaling from inside cell may lead to serious health problems

Angiogenesis inhibitors that block a tumor's development of an independent blood supply have been touted as effective cancer fighters that result in fewer side effects than traditional chemotherapy.

24 Aug 2007

Age-related macular degeneration patient receives investigational eye drops

An 88-year-old man at The Methodist Hospital in Houston is one of two patients in the world today to receive an investigational eye drop that may restore sight for those suffering from neovascular (wet) age-related macular degeneration, a major cause of central visual loss and one of the leading causes of blindness in people over 60 in the United States.

17 Aug 2007

New pathway for inflammation-induced cancer

A well-known inflammatory protein spawns an enzyme that inactivates two tumor-suppressing genes, ultimately triggering production of new blood vessels to nourish breast cancer cells, researchers at The University of Texas M. D. Anderson Cancer Center report in the August edition of the journal Cell .

11 Aug 2007

Protein kinase G holds promise for cancer treatment

An enzyme that cancer cells eliminate, apparently so they can keep proliferating, may hold clues to more targeted, effective cancer treatment, scientists say.

19 Jul 2007

St. Jude study holds promise for improving neuroblastoma treatment

A treatment for neuroblastoma that lands a one-two punch works best when the second punch is timed to take maximum advantage of the first one, according to results of studies at St. Jude Children's Research Hospital.

12 Jul 2007

A view on new drugs for macular degeneration

Restricting use of drugs for macular degeneration to patients who have already gone blind in one eye is "unacceptable" concludes the July issue of Drug and Therapeutics Bulletin (DTB).

4 Jul 2007

Chronic methamphetamine abuse linked to cardiovascular disease

The study is being published the week of June 25 in an advanced online edition of the Proceedings of the National Academy of Sciences.

26 Jun 2007

Basically eating fish may protect against type of blindness

Increasing intake of the omega-3 fatty acids DHA and EPA, found in popular fish-oil supplements, may protect against blindness resulting from abnormal blood vessel growth in the eye, according to a study published online by the journal Nature Medicine on June 24.

26 Jun 2007

Avastin helps those with radiation retinopathy

Patients with radiation retinopathy who were destined to go blind within five years now can keep their sight longer through localized treatment with Avastin, a well-known cancer drug, according to a two-year study published in the June, 2007 Archives of Ophthalmology.

23 Jun 2007

Angiogenesis gene polymorphisms predict tumor recurrence in stage II and III colon cancer

Researchers at the University of Southern California (USC) have identified specific molecular markers that may help to predict tumor recurrence in stage II and III colon cancer patients.

8 Jun 2007

VEGF Trap (aflibercept) shows activity in patients with advanced ovarian cancer

Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.

5 Jun 2007

Study shows combination improves survival of metastatic melanoma patients

Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented at the 2007 American Association of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2007

Axitinib shows promise in treatment of advanced thyroid cancer

The investigational drug axitinib produced tumor regression or stable disease in almost three-out-of-four patients with advanced thyroid cancer, a research team reported at the annual meeting of the American Society for Clinical Oncology in Chicago.

5 Jun 2007

Results of phase II studies of pazopanib

GlaxoSmithKline (GSK) has announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.

5 Jun 2007

Blood test may help signal tumor's remission, return in throat cancer patients

A blood test that detects proteins commonly released by a growing tumor could one day become a useful tool for monitoring the effectiveness of chemotherapy and radiation treatment in people with advanced throat cancer, according to a study published in the June 1, 2007, issue of Clinical Cancer Research .

3 Jun 2007

Celecoxib offers promise for premature babies

Scientists have found evidence that the cox-2 inhibitor celecoxib, a common pain reliever used to treat arthritis, may offer a new way to reduce the risk of the most common cause of brain damage in babies born prematurely.

18 May 2007